Translational research/biomarkers最新文献

{"title":"2022-RA-818-ESGO BIUXX","authors":"B. Choi, Hyojin Kim, K. Kim","doi":"10.1136/ijgc-2022-esgo.873","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.873","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"271 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122703779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-366-ESGO Calcium activated potassium channels (KCNMA1) as biomarker of pre invasive and invasive cervical cancer","authors":"B. Gupta, Puja Kumari, S. Rajaram, R. Kar, P. Gogoi, S. Jain","doi":"10.1136/ijgc-2022-esgo.866","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.866","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114922793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1126-ESGO Mesenchymal prognostic signature in ovarian cancer","authors":"K. Lisowska, K. Kujawa, J. Syrkis, A. Cortez, Patrycja Jakubowska","doi":"10.1136/ijgc-2022-esgo.882","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.882","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116638972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1136-ESGO A single-cell map of rare ovarian cancer","authors":"T. Laga, P. Busschaert, S. Olbrecht, L. Loverix, F. Lodi, T. Baert, T. Gorp, A. V. Rompuy, I. Vergote, D. Lambrechts, E. Nieuwenhuysen","doi":"10.1136/ijgc-2022-esgo.884","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.884","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122187169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1251-ESGO P-cadherin: a promising prognostic biomarker for homologous repair proficient high grade serous ovarian carcinoma","authors":"R. Canario, Inês Morgado, A. Ribeiro, N. Mendes, P. Lopes, M. Teixeira, C. Bartosch, J. Paredes","doi":"10.1136/ijgc-2022-esgo.889","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.889","url":null,"abstract":"acquired platinum resistance in many cases, and emerging evidence suggests epigenetic alterations may be critical. We wish to investigate epigenetic changes that may drive platinum resistance in HGSC by treating established HGSC cell lines and patient-derived cells with pulses of carboplatin and investigating the nature, kinetics and plasticity of platinuminduced epigenetic changes. Methodology We will mimic, using in an in vitro two-dimensional model, multiple cycles of platinum-based chemotherapy as used clinically. We will generate preliminary results from established cell lines and primary cultures. The primary cell cultures are collected from the ascites of patients with HGSC treated at Imperial College NHS Trust, London. Following validation (p53, PAX8 immunocytochemistry), carboplatin sensitivity is assessed (sulforhodamine B assay). Cells are then pulsed with four cycles of carboplatin (50mM for 6 hours) with a week of recovery between each cycle. Chemosensitivity of surviving cells is measured after each cycle. The cells are then harvested for downstream methylation (Illumina 850k array), transcriptomic (RNA sequencing) and chromatin accessibility (ATAC sequencing) assays. Cells are also imaged using STORM (Stochastic Optical Reconstruction Microscopy). Preliminary STORM data already indicate differences in chromatin structure and the distribution of specific histone modifications between paired sensitive and resistant HGSC cell lines. Results We will receive the raw data within 8–12 weeks from now for the bioinformatic analysis. Differential gene expression analysis will uncover differently enriched pathways under the selective pressure of platinum-based chemotherapy. Conclusion Understanding the epigenetic landscape of HGSC in real time using physiologically relevant models will allow us to identify possible therapeutic targets that could eventually prevent platinum resistance.","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"83 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126015262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-793-ESGO TROP-2 expression and the tumor immune-microenvironment in cervical cancer","authors":"Y. Chiba, S. Yazaki, Y. Kojima, H. Yoshida, S. Takamizawa, R. Kitadai, A. Saito, H. Okuma, T. Nishikawa, T. Shimoi, K. Sudo, E. Noguchi, M. Uno, M. Ishikawa, Tomoyasu Kato, Y. Fujiwara, K. Yonemori","doi":"10.1136/ijgc-2022-esgo.870","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.870","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"262 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114430292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-457-ESGO Prognostic role of TGF-β signalling pathway alterations in endometrial cancers – a prospective clinical study","authors":"D. Bose, P. Rema","doi":"10.1136/ijgc-2022-esgo.867","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.867","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125268806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1195-ESGO Longitudinal study of vaginal microbiome pre- and post-treatment identifies biomarkers for cervical intraepithelial neoplasia 3 (CIN3)","authors":"D. Ścibior-Bentkowska, C. Banila, B. Nedjai","doi":"10.1136/ijgc-2022-esgo.886","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.886","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124372854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-968-ESGO Immunotherapy response monitoring using personalized circulating tumor DNA analysis in patients with relapsed gynecologic malignancies","authors":"K. Castaneda, J. Saldivar, Y. Chae, H. Sindhu, Concepcion R. Diaz-Arrastia, K. Grzankowski, G. Azzi, C. Scalise, E. Kalashnikova, Brittany Nicosia, Shilpa R. Tekula, A. Aleshin, A. ElNaggar","doi":"10.1136/ijgc-2022-esgo.879","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.879","url":null,"abstract":"2022-RA-945-ESGO Table 1 Methodology GARNET (NCT02715284) is a phase 1, multicentre, open-label, single-arm study of dostarlimab in patients with advanced/recurrent solid tumours. Three expansion cohorts enrolled patients based on MMR status: dMMR (A1) and MMRp (A2) advanced/recurrent EC, and dMMR non-EC solid tumours (F). Patients received dostarlimab 500 mg IV Q3W for 4 cycles, then 1000 mg IV Q6W until progression or discontinuation. TMB and PDL1 were exploratory biomarkers. TMB status was determined by FoundationOne test; TMB-high (TMB-H) was defined as 10 mutations/Mb. PDL1 expression was determined by combined positive score (CPS) by Ventana assay; PDL1-high (PDL1-H) was defined as CPS 1. The study was not powered to assess antitumour activity within subgroups. Results TMB-H and PDL1-H were common in dMMR solid tumours; PDL1-H was observed in 39.4% of MMRp EC tumours (table 1). Objective response rate (ORR) was higher in patients with TMB-H/PDL1-H tumours (55.6% for all cohorts, combined; Table). Safety for each cohort was previously reported. Conclusion PDL1-H and TMB-H were frequently observed in the dMMR EC and non-EC cohorts, regardless of tumour type; PDL1-H was also prevalent in MMRp EC tumours. Although not a powered analysis, ORR by BICR per RECIST v1.1 was higher in patients with TMB-H and PDL1-H solid tumours. Across cohorts, dMMR status was predictive of response. REFERENCE 1. Andre T, et al. Ann Oncol 2021;32(suppl 5):S829-S866. 991P. 2022-RA-968-ESGO IMMUNOTHERAPY RESPONSE MONITORING USING PERSONALIZED CIRCULATING TUMOR DNA ANALYSIS IN PATIENTS WITH RELAPSED GYNECOLOGIC MALIGNANCIES Kayla Castaneda, Jose Salvador Saldivar, Young Kwang Chae, Hemant Sindhu, Concepcion Diaz-Arrastia, Kassondra Grzankowski, Georges Azzi, Carly Bess Scalise, Ekaterina Kalashnikova, Brittany Nicosia, Shilpa Tekula, Alexey Aleshin, Adam C ElNaggar. Spero Women’s Oncology Center, El Paso, TX; Northwestern University Feinberg School of Medicine, Chicago, IL; Southwest Cancer Care, Sierra Vista, AZ; Memorial Hermann, Houston, TX; Austin Cancer Center, Austin, TX; Holy Cross Health, Ft. Lauderdale, FL; Natera, Inc., Austin, TX 10.1136/ijgc-2022-ESGO.879 Introduction/Background Immunotherapy has transformed cancer care. Unfortunately, responses within gynecologic malignancies have been modest when compared to other disease sites. Biomarkers for early determination of treatment benefit are urgently needed to spare unnecessary toxicity and cost. We evaluated if circulating tumor DNA (ctDNA) dynamics enable early detection of progressive disease (PD) and treatment response in patients with recurrent, gynecologic malignancies receiving immunotherapy. Methodology Longitudinal plasma samples (n=138) were collected from 25 patients with recurrent cervical (N=6), endometrial (N=12), or ovarian (N=7) cancers who received immunotherapy. A personalized, tumor-informed multiplex PCR assay (Signatera bespoke mPCR NGS assay) was used for the detection of ctDNA in plasma","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"133 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124437376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2022-RA-1697-ESGO Evaluation of advanced lung cancer inflammation index as a prognostic factor in patients with ovarian cancer treated with primary debulking surgery","authors":"U. Palo, D. Mondal, Anik Ghosh, B. Chakraborti, J. Bhaumik","doi":"10.1136/ijgc-2022-esgo.902","DOIUrl":"https://doi.org/10.1136/ijgc-2022-esgo.902","url":null,"abstract":"","PeriodicalId":406851,"journal":{"name":"Translational research/biomarkers","volume":"74 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133494831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}